Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT)

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 6, 2009, Pages 745-754

  Lüke, Matthias ^a,b   Ziemssen, Focke ^b   Vöker, Michael ^b   Altpeter, Elke ^b   Beutel, Julia ^a,b   Besch, Dorothea ^b   Bartz Schmidt, Karl Ulrich ^b   Gelisken, Faik ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Age related macular degeneration; Best corrected visual acuity; Contrast sensitivity; Macular translocation; Near visual acuity; Photodynamic therapy; Vision related quality of life

Indexed keywords

VERTEPORFIN;

ADULT; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; HUMAN; INTERMETHOD COMPARISON; MUSCLE HYPOTONIA; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA MACULA TRANSLOCATION; RETINA MALFORMATION; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT RESPONSE; VISION; VISUAL ACUITY; VITRECTOMY;

CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; HISTORY, 17TH CENTURY; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PORPHYRINS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 67349235948     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1050-5     Document Type: Article

References (32)

1. Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99:933-943
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432-1444. doi: 10.1056/NEJMoa062655
3. Pieramici DJ, Avery RL (2006) Ranibizumab: Treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther 6(11):1237-1245. doi: 10.1517/14712598.6.11.1237
4. Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, Grisanti S, Herzau V, Bartz-Schmidt KU (2007) Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 245(8):1085-1095. doi: 10.1007/s00417-006-0524-y
5. Lüke M, Ziemssen F, Bartz-Schmidt KU, Gelisken F (2007) Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration - a report of 1 year results. Graefes Arch Clin Exp Ophthalmol 245(12):1831-1836. doi: 10.1007/ s00417-007-0558-9
6. Ziemssen F, Lüke M, Bartz-Schmidt KU, Gelisken F (2008) Time-dependent effects on contrast sensitivity, near and distance acuity: Difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). Graefes Arch Clin Exp Ophthalmol 246(5):653-659. doi: 10.1007/ s00417-007-0726-y
7. Colenbrander A, Fletcher DC (1990) Visual acuity measurements in low vision patients. J Vis Rehabil 4:1-9
8. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, National Eye Visual Function Questionnaire Field Test Investigators (2001) Development of the 25-item National eye institute visual function questionnaire. Arch Ophthalmol 119:1050-1058
9. Stelmack JA, Stelmack TR, Massof RW (2002) Measuring low-vision rehabilitation outcomes with the NEI VFQ-25. Invest Ophthalmol Vis Sci 43:2859-2868
10. Clemons TE, Chew EY, Bressler SB, McBee W, for the AREDS Research Group (2003) National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). Arch Ophthalmol 121:211-217
11. Mangione CM, Berry S, Spritzer K (1998) Identifying the content area for the 51-item National Eye Institute Visual Function Questionaire: Results from focus groups with visually impaired persons. Arch Ophthalmol 116:227-233
12. Franke GH, Esser J, Voigtländer A, Mähner N (1998) Der National Eye Institute Visual Function Questionnaire (NEI-VFQ) - Erste Ergebnisse zur psychometrischen Überprüfung eines Verfahrens zur Erfassung der Lebensqualität bei Sehbeeinträchtigten. Z Mol Psychol 7:178-184
13. Mangione CM (2000) The NEI VFQ-25 Scoring Algorithm. http://catalog.nei.nih.gov/productcart/pc/viewPrd.asp?idcategory= 50&idproduct=60#)
14. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of two randomized clinical trials. TAP Report 1. Arch Ophthalmol 117:1329-1345
15. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of two randomized clinical trials. TAP Report 2. Arch Ophthalmol 119:198-207
16. Eckardt C, Eckardt U, Conrad H-G (1999) Macular rotation with or without counter-rotation of the globe of the patients with agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol 237:313-325. doi: 10.1007/ s004170050239
17. Aisenbrey S, Lafaut BA, Szurman P, Grisanti S, Luke C, Krott R, Thumann G, Fricke J, Neugebauer A, Hilgers RD, Esser P, Walter P, Bartz-Schmidt KU (2002) Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 120:451-459
18. Abdel-Meguid A, Lappas A, Hartmann K, Auer F, Schrage N, Thumann G, Kirchhof B (2003) One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol 87:615-621. doi: 10.1136/bjo.87.5.615
19. Mruthyunjaya P, Stinnett SS, Toth CA (2004) Change in visual function after macular translocation with 360° retinectomy for neovascular age-related macular degeneration. Ophthalmology 111:1715-1724. doi: 10.1016/j.ophtha.2004.03.022
20. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy (2000) Macular degeneration: Do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 84:244-250. doi: 10.1136/bjo.84.3.244
21. Tejeria L, Harper RA, Artes PH, Dickinson CM (2007) Face recognition in age related macular degeneration: Perceived disability, measured disability, and performance with a bioptic device. Br J Ophthalmol 86:1019-1026. doi: 10.1136/bjo.86.9.1019
22. Patel I, Turano KA, Broman AT, Bandeen-Roche K, Munoz B, West SK (2006) Measures of visual function and percentage of preferred walking speed in older adults. Invest Ophthalmol Vis Sci 47:65-71. doi: 10.1167/ iovs.05-0582
23. Lord SR, Clark RD, Webster IW (1991) Visual acuity and contrast sensitivity in relation to falls in an elderly population. Age Ageing 20:175-181. doi: 10.1093/ageing/20.3.175
24. Lee HKM, Scudds RJ (2003) Comparison of balance in older people with and without visual impairment. Age Ageing 32:643-649. doi: 10.1093/ageing/ afg110
25. Cahill MT, Stinnett SS, Banks AD, Freedman SF, Toth CA (2005) Quality of Life after Macular Translocation with 360° Peripheral Retinectomy for Age-Related Macular Degeneration. Ophthalmology 112:144-151. doi: 10.1016/j.ophtha.2004.06.035
26. Hewitt AW, Jeganathan SV, Kidd JE, Pesudovs K, Verma N (2006) Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life. Graefes Arch Clin Exp Ophthalmol 244(8):972-977. doi: 10.1007/s00417-005-0218-x
27. Armbrecht AM, Aspinall PA, Dhillon B (2004) A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol 88:1270-1273. doi: 10.1136/bjo.2003.038604
28. Cahill MT, Banks AD, Stinnett SS, Toth CA (2005) Vision-Related Quality of Life in Patients with Bilateral Severe Age-related Macular Degeneration. Ophthalmology 112(1):152-158. doi: 10.1016/ j.ophtha.2004.06.036
29. Casten RJ, Rovner BW, Tasman W (2004) Age-related macular degeneration and depression: A review of recent research. Curr Opin Ophthalmol 15(3):181-183. doi: 10.1097/01.icu.0000120710.35941.3f
30. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI (2001) Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 108(10):1893-1900. doi: 10.1016/S0161-6420(01)00754-0
31. Yang Y, ANCHOR study group (2007) Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3 mg and 0.5 mg with verteporfin photodynamic therapy for predominantly classic CNV lesions secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 48:A4545
32. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR (2007) MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol 125(11):1460-1469